Axogen, Inc.

Axogen, Inc. is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company breaks its total addressable market into four categories: extremities, oral maxillofacial and head and neck, breast reconstruction neurotization, and urology. The company previously estimated that U.S. peripheral nerve injury has a potential TAM for its current product portfolio and believes it is presently at least $5.6 billion. The extremities portion of the TAM is estimated to be at least $2.9 billion annually, the oral maxillofacial portion at least $1.2 billion annually, the breast portion at least $417 million annually with an additional at least $260 million from implant-based procedures, and the urology portion at least $754.0 million or 110,000 procedures.

The company competes primarily against all transected and non-transected peripheral nerve repair approaches, including direct suture repair, autograft, and hollow-tube nerve conduits and materials used to wrap and protect damaged peripheral nerve tissue. Major competitors' products include off-the-shelf repair options in hollow-tube conduits, coaptation aids and bio-absorbable wraps. The company believes its intellectual property, including patents, patents-pending, trade secrets, and unique internal subject matter expertise, is an important barrier for its Avance Products and Axoguard products. The company also believes its ability to offer a portfolio of products focused on peripheral nerve repair and the breadth of clinical data provides a unique competitive position versus other entities that do not have this breadth of product offering.

The company generates revenue primarily through the distribution of its portfolio of products for peripheral nerve repair, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Revenue from the distribution of these products in the U.S. is the main contributor to total reported sales and has been the key component of growth to date. The company provides products to hospitals, surgery centers and military hospitals, calling on surgeons including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, certain oral and maxillofacial surgeons, and urologists. As of December 31, 2025, the company had 138 direct sales professionals in the U.S., supplemented by independent sales agencies that represent approximately 8% of total revenue.

Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site, with more than 17 years of comprehensive clinical evidence and more than 120,000 implants since launch. On December 3, 2025, the FDA approved the BLA for Avance as an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory nerve discontinuity (≤25mm), with accelerated approval for sensory nerve discontinuity (>25mm) and mixed and motor nerve discontinuity. Commercial availability of Avance is expected early in the second quarter of 2026. The Axoguard Product Line includes Axoguard Nerve Connector, a coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector, used to wrap and protect damaged peripheral nerves; Axoguard HA+ Nerve Protector, a next-generation technology designed to enhance nerve gliding; and Axoguard Nerve Cap, used to protect a peripheral nerve end to reduce the development of symptomatic or painful neuroma. Avive+ Soft Tissue Matrix is a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue healing, launched on June 24, 2024.

On December 3, 2025, the FDA approved the BLA for Avance, and the APC Facility is now registered with the FDA as a biologics manufacturing facility. The company obtained certain economic development grants from state and local authorities totaling up to $2.7 million including $1.3 million of cash grants to offset costs to acquire and develop the APC Facility. In October 2025, the company received notification from certain grant authorities that it is expected to satisfy its job creating milestone, assuming it continues to maintain certain headcount and payroll amount thresholds through December 31, 2026, and if unable to maintain minimum requirements, could be obligated to pay back up to approximately $950 thousand as of December 31, 2025 related to these grants. The company's RANGER clinical study has enrolled more than 2,800 Avance Nerve Graft repairs to date, and enrollment in the primary RANGER arms and the MATCH arm were completed in December 2023. Enrollment was completed for COVERED in March 2025, and enrollment in REPOSE XL was completed in January 2025. The RECON study, a pivotal Phase III trial, has successfully completed enrollment, follow-up, and analysis, with three peer-reviewed publications published. The company's Sensation-NOW arm completed enrollment in November 2025.

For the fiscal year ended December 31, 2025, total revenues were $196.995 million compared to $179.574 million in 2024 and $155.126 million in 2023. Net loss was $15.7 million for 2025, compared to $10.0 million for 2024 and $21.7 million for 2023. As of December 31, 2025, the company had an accumulated deficit of approximately $307.0 million. Gross profit was $147.895 million in 2025, compared to $133.648 million in 2024 and $113.419 million in 2023. The company invested approximately $32.9 million in research and development activities in 2025.

The company believes that near-term growth can be supported first through expanded productivity of its existing sales force as they go into more depth with existing accounts and then by adding additional accounts. The company expects the number of direct sales professionals to increase over time. The company believes additional opportunities exist to develop or acquire complementary products in peripheral nerve repair as well as opportunities to expand the existing portfolio of products in new applications such as lower extremity surgery, head and neck surgery, urology, and the surgical treatment of pain. The company estimates that there is an additional 10-15% of breast reconstructions done with implants that can also be neurotized which adds at least $260 million to increase the estimated TAM to at least $677 million annually. The company believes that expanding its products into lower extremity surgery, urology, and the surgical treatment of pain could offer expanded revenue opportunities.

The company believes that further innovation and product development is needed to maintain its leadership position and provide expansion opportunities. The company is focusing on creating balanced revenue growth and yield improvements in product processing. The company has experienced unanticipated operating challenges as it commenced processing operations at the APC Facility, which have negatively impacted gross margins. The company expects the APC Facility, along with the ability for expansion, will provide processing capabilities that will meet its intended sales growth.

The company expects to continue to rely on the Dayton Facility for the processing of Avive+ Soft Tissue Matrix, with the current License and Services Agreement extending through December 31, 2026. The company's processing methods and process controls have been developed and validated to ensure product uniformity and quality. The company believes that its manufacturing process for Avance is scalable and will enable it to manufacture Avance in commercial quantities in compliance with applicable laws and regulations. As of December 31, 2025, the company had 622 employees, substantially all of whom were full-time.

For the fiscal year ended December 31, 2025, the company invested approximately $32.9 million in research and development activities. The company obtained certain economic development grants from state and local authorities totaling up to $2.7 million including $1.3 million of cash grants to offset costs to acquire and develop the APC Facility. The filing does not discuss specific share repurchase authorization amounts or dividend policy.

The company faces headwinds including that approximately 60% of total revenues are from sales of Avance Products and any adverse decision from the FDA would negatively impact operations and financial condition. The company has a history of net losses and has not consistently experienced positive cash flow from operations, having incurred net losses of $15.7 million, $10.0 million, and $21.7 million for the years ended December 31, 2025, 2024 and 2023, respectively. The company is operating in a period of economic uncertainty and capital markets volatility driven in part by growing geopolitical tensions and evolving global security risks. The company's revenue depends upon prompt and adequate reimbursement from public and private insurers, and approximately 65% of commercially insured patients in the U.S. have coverage for procedures utilizing its products.

The company faces constraints including that portions of the FDA-approved indication for Avance were granted under the FDA's accelerated approval program, and continued approval for these indications is contingent upon timely completion of required post-marketing confirmatory studies with a final protocol due February 5, 2026, study completion by December 5, 2030, and a final report due June 5, 2031. The company is highly dependent on the continued availability of its facilities and could be harmed if it continues to experience operating challenges with its APC Facility. The company's estimates of the TAM for peripheral nerve repair and reconstruction may be inaccurate, and the company's growth prospects and financial performance could be materially adversely affected if the TAM is smaller than anticipated.

Approximately 60% of total revenues are from sales of Avance Products, and any adverse FDA action following BLA approval on December 3, 2025 that withdraws or suspends the BLA, narrows the approved indication, or otherwise limits commercialization would have a material negative impact on revenues and operations. Portions of the FDA-approved indication for Avance were granted under the accelerated approval pathway, and continued approval for sensory nerve discontinuity (>25mm) and mixed and motor nerve discontinuity is contingent upon a post-marketing requirement study with a final protocol due February 5, 2026, study completion by December 5, 2030, and a final report due June 5, 2031; failure to verify clinical benefit could result in withdrawal of these indications. The company has a history of net losses, having incurred net losses of $15.7 million, $10.0 million, and $21.7 million for the years ended December 31, 2025, 2024 and 2023, respectively, and as of December 31, 2025 had an accumulated deficit of approximately $307.0 million. The company is highly dependent on the continued availability of its APC Facility and has experienced unanticipated operating challenges there that have negatively impacted gross margins. The company's revenue depends upon prompt and adequate reimbursement from third-party payors, and approximately 65% of commercially insured patients in the U.S. have coverage for procedures utilizing its products, leaving a significant coverage gap.

Management's message emphasizes the company's position as the leading company focused specifically on peripheral nerve regeneration and repair, highlighting the FDA approval of the BLA for Avance on December 3, 2025 as a significant milestone. The company's strategic priorities include increasing awareness of its products through educational conferences and presentations, expanding clinical and scientific data regarding product performance, developing deeper penetration with existing accounts through development of long-term users, increasing patient access via improved coverage and payment, and expanding the product pipeline and applications in peripheral nerve repair. Management believes that near-term growth can be supported first through expanded productivity of the existing sales force with existing accounts and then by adding additional accounts. The company expects commercial availability of Avance early in the second quarter of 2026.